Priority Driven Collaborative Priority-driven Cancer Research Scheme Collaborative Queensland (PDCCRS) 2012: Germline Cancer Cancer Institute of Medical Copy Number Variants are $24,420.50 01/06/2013 19 Herston 4028 Australia Research Research Genetic Risk Factors for Scheme Familial Colorectal Cancer. Appl ID 1052035 Priority Driven Collaborative Cancer Research Scheme Priority-driven (PDCCRS) 2012: RAD51 Collaborative Queensland overexpression regulates Cancer Cancer Institute of Medical gene expression $24,764 01/06/2013 12 Herston 4028 Australia Research Research profiles of aggressive Scheme metastatic triple negative breast cancer. Appl ID 1050903 Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A Phase II study to evaluate the safety Priority-driven and potential benefit of Collaborative intraperitoneal (IP) Cancer University of The University of Cancer bevacizumab to control $277,958 28/06/2013 36 2006 Australia Sydney Sydney, NSW Research symptomatic malignant Scheme ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101). Appl ID 1050134 Priority Driven Collaborative Priority-driven Cancer Research Scheme Collaborative Queensland (PDCCRS) 2013: Identification Cancer Cancer Institute of Medical of novel permissive mutations $50,000 04/02/2014 47 Herston, QLD 4028 Australia Research Research representing acquired Scheme vulnerabilities in lung cancer - CA-A1314/20 ApplID: 1070515 2013 Priority-driven Priority-driven Collaborative Cancer Collaborative Walter and Eliza Cancer Research Scheme (PdCCRS): Cancer Hall Institute of $27,500 15/02/2014 12 Parkville, VIC 3052 Australia Regulating BAK and BAX Research Medical Research conversion to death-inducing Scheme oligomers. App1069567 -
Cancer Australia Priority-driven Collaborative Cancer Research Scheme Queensland Institute of Medical Research Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: Germline Copy Number Variants are Genetic Risk Factors for Familial Colorectal Cancer. Appl ID 1052035 $24,420.50 01/06/2013 19 Herston 4028 Cancer Australia Priority-driven Collaborative Cancer Research Scheme Queensland Institute of Medical Research Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: RAD51 overexpression regulates gene expression profiles of aggressive metastatic triple negative breast cancer. Appl ID 1050903 $24,764 01/06/2013 12 Herston 4028 Cancer Australia Priority-driven Collaborative Cancer Research Scheme University of Sydney Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2012: A Phase II study to evaluate the safety and potential benefit of intraperitoneal (IP) bevacizumab to control symptomatic malignant ascites in patients with chemotherapy resistant ovarian cancers: REZOLVE (ANZGOG-1101). Appl ID 1050134 $277,958 28/06/2013 36 The University of Sydney, NSW 2006 Cancer Australia Priority-driven Collaborative Cancer Research Scheme Queensland Institute of Medical Research Priority Driven Collaborative Cancer Research Scheme (PDCCRS) 2013: Identification of novel permissive mutations representing acquired vulnerabilities in lung cancer - CA-A1314/20 ApplID: 1070515 $50,000 04/02/2014 47 Herston, QLD 4028 Cancer Australia Priority-driven Collaborative Cancer Research Scheme Walter and Eliza Hall Institute of Medical Research 2013 Priority-driven Collaborative Cancer Research Scheme (PdCCRS): Regulating BAK and BAX conversion to death-inducing oligomers. App1069567 - $27,500 15/02/2014 12 Parkville, VIC 3052
grants_reporting_20170922.docx